Compare · LLY vs MNPR
LLY vs MNPR
Side-by-side comparison of Eli Lilly and Company (LLY) and Monopar Therapeutics Inc. (MNPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and MNPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 1383.7x MNPR ($789.2M).
- LLY has been more active in the news (16 items in the past 4 weeks vs 14 for MNPR).
- LLY has more recent analyst coverage (25 ratings vs 15 for MNPR).
- Company
- Eli Lilly and Company
- Monopar Therapeutics Inc.
- Price
- $1159.75+0.10%
- $117.52+4.32%
- Market cap
- $1.09T
- $789.2M
- 1M return
- +3.44%
- -
- 1Y return
- +57.83%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 16
- 14
- Recent ratings
- 25
- 15
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Latest LLY
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
Latest MNPR
- Amendment: Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan and exercised 4,090 shares at a strike of $22.04 (SEC Form 4)
- Amendment: Director Anderson Raymond exercised 3,142 shares at a strike of $30.00 and sold $351,835 worth of shares (3,142 units at $111.98) as part of a pre-agreed trading plan (SEC Form 4)
- Acting Chief Medical Officer Rioux Patrice exercised 1,380 shares at a strike of $0.01 and sold $111 worth of shares (1 units at $111.26) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 5,065 units (SEC Form 4)
- Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 7,396 units (SEC Form 4)
- Director Anderson Raymond sold $351,189 worth of shares (3,142 units at $111.77) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 23,751 units (SEC Form 4)
- SEC Form 144 filed by Monopar Therapeutics Inc.
- SEC Form 144 filed by Monopar Therapeutics Inc.
- SEC Form 144 filed by Monopar Therapeutics Inc.
- Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
- Monopar Therapeutics downgraded by Cantor Fitzgerald with a new price target